InspireMD Inc Stock

$2.36

2.88% day before yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US45779A8466

Symbol

NSPR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

InspireMD Inc Stock price

$2.36

-4.40 65.07% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-0.07 2.88%

ISIN

US45779A8466

Symbol

NSPR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$72.3m

Enterprise Value

$46.3m

Net debt

positive

Cash

$26.0m

Shares outstanding

30.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

10.3 | 9.8

EV/Sales

6.6 | 6.3

EV/FCF

negative

P/B

2.6

Financial Health

Equity Ratio

76.6%

Return on Equity

-88.9%

ROCE

-117.3%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$7.0m | $7.3m

EBITDA

$-36.8m | $-47.0m

EBIT

$-37.1m | $2.2m

Net Income

$-36.0m | $-30.8m

Free Cash Flow

$-27.3m

Growth (TTM | estimate)

Revenue

8.5% | 4.8%

EBITDA

-53.6% | -39.4%

EBIT

-53.4% | 106.5%

Net Income

-58.5% | 3.9%

Free Cash Flow

-59.0%

EPS

$-0.7

FCF per Share

$-0.9

Short interest

0.9%

Employees

Rev per Employee

$80.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

InspireMD Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a InspireMD Inc forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a InspireMD Inc forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from InspireMD Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	7.03 7.03	8% 8% 100%
- Direct Costs	5.53 5.53	16% 16% 79%
Gross Profit	1.50 1.50	13% 13% 21%
- Selling and Administrative Expenses	24 24	40% 40% 341%
- Research and Development Expense	- -	- -
EBITDA	-37 -37	54% 54% -523%
- Depreciation and Amortization	0.31 0.31	29% 29% 4%
EBIT (Operating Income) EBIT	-37 -37	53% 53% -528%
Net Profit	-36 -36	59% 59% -512%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

InspireMD Inc Stock News

Neutral

GlobeNewsWire

●

4 days ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following its premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA). The CGuard Prime was engineered specifica...

Neutral

GlobeNewsWire

●

19 days ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States.

Neutral

GlobeNewsWire

●

30 days ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS.

More InspireMD Inc News

Company Profile

InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Head office	United States
CEO	Marvin Slosman
Employees	86
Founded	2005
Website	www.inspiremd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now